FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yves Humblet

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Hematopoietic Stem Cells

Co-author Network

Publications

TOP 3
E Seront; M Sterckx; Yves Humblet; Jean-Pascal Machiels; M Mano; F Mazzeo; Jean-François Baurain
New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.
Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Bart Jacobs; Wendy De Roock; Hubert Piessevaux; Robin Van Oirbeek; Bart Biesmans; Joris De Schutter; Steffen Fieuws; Jo Vandesompele; M Peeters; Jean-Luc Van Laethem; Yves Humblet; Frederique Pénault-Llorca; Gert De Hertogh; Pierre Laurent-Puig; Eric Van Cutsem; Sabine Tejpar
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yves Humblet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: E Seront; M Sterckx; Yves Humblet; Jean-Pascal Machiels; M Mano; F Mazzeo; Jean-François Baurain
New drugs in medical oncology: new difficulties to distinguish drug-induced side effects from cancer complications: a case-report.
Acta clinica Belgica 2011;66(6):426-8.
2010: Jean-Yves Douillard; Salvatore Siena; James Cassidy; Josep Tabernero; Ronald Burkes; Mario Barugel; Yves Humblet; György Bodoky; David Cunningham; Jacek Jassem; Fernando Rivera; Ilona Kocákova; Paul Ruff; Maria Błasińska-Morawiec; Martin Šmakal; Jean-Luc Canon; Mark Rother; Kelly S Oliner; Michael Wolf; Jennifer Gansert
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(31):4697-705.
2009: Bart Jacobs; Wendy De Roock; Hubert Piessevaux; Robin Van Oirbeek; Bart Biesmans; Joris De Schutter; Steffen Fieuws; Jo Vandesompele; M Peeters; Jean-Luc Van Laethem; Yves Humblet; Frederique Pénault-Llorca; Gert De Hertogh; Pierre Laurent-Puig; Eric Van Cutsem; Sabine Tejpar
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):5068-74.
2009: Eric Van Cutsem; Walter L Vervenne; Jaafar Bennouna; Yves Humblet; Sharlene Gill; Jean-Luc Van Laethem; Chris Verslype; Werner Scheithauer; Aijing Shang; Jan Cosaert; Malcolm J Moore
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2231-7.
2008: Nicola Personeni; Steffen Fieuws; Hubert Piessevaux; Gert De Hertogh; Joris De Schutter; Bart Biesmans; Wendy De Roock; An Capoen; Maria Debiec-Rychter; Jean-Luc Van Laethem; Marc Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(18):5869-76.
2008: W De Roock; Hubert Piessevaux; Joris De Schutter; M Janssens; Gert De Hertogh; Nicola Personeni; B Biesmans; Jean-Luc Van Laethem; M Peeters; Yves Humblet; Eric Van Cutsem; Sabine Tejpar
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(3):508-15.
2008: Eric Van Cutsem; Salvatore Siena; Yves Humblet; Jean-Luc Canon; J Maurel; Emilio Bajetta; Bart Neyns; Dusan Kotasek; A Santoro; W Scheithauer; S Spadafora; Rafael G Amado; N Hogan; M Peeters
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(1):92-8.
2007: S Siena; M Peeters; Eric Van Cutsem; Yves Humblet; P Conte; Emilio Bajetta; D Comandini; György Bodoky; G Van Hazel; T Salek; M Wolf; G Devercelli; M Woolley; Rafael G Amado
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.
British journal of cancer 2007;97(11):1469-74.
2007: Josep Tabernero; Eric Van Cutsem; Eduardo Díaz-Rubio; Andrés Cervantes; Yves Humblet; Thierry André; Jean-Luc Van Laethem; Patrick Soulié; Esther Casado; Chris Verslype; Javier Sastre Valera; Giampaolo Tortora; Fortunato Ciardiello; Oliver Kisker; Aimery de Gramont
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5225-32.
2007: S Delande; Pierre Goffette; Catherine Verbaandert; Jacques Rahier; Carlos Graux; F Mazzeo; Yves Humblet; Jean-Pascal Machiels
Bronchobiliary fistula and cholangiocarcinoma: a case report and principles of management.
Acta clinica Belgica 2007;62(6):438-41.
2007: Catherine Hubert; Christine Sempoux; yves horsmans; Jacques Rahier; Yves Humblet; Jean-Pascal Machiels; Antonino Ceratti; Jean-Luc Canon; Jean-François Gigot
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Liver international : official journal of the International Association for the Study of the Liver 2007;27(7):938-43.
2007: Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(13):1658-64.
2007: Jean-Pascal Machiels; Christine Sempoux; Pierre Scalliet; J-C Coche; Yves Humblet; Eric Van Cutsem; Joseph Kerger; Jean-Luc Canon; M Peeters; S Aydin; S Laurent; Alex Kartheuser; B Coster; Sarah Roels; J-F Daisne; B Honhon; Lionel DUCK; C Kirkove; M-A Bonny; Karin Haustermans
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):738-44.
2006: Sylvie Giacchetti; Georg Bjarnason; Carlo Garufi; Dominique Genet; Stefano Iacobelli; Marco Tampellini; Rune Smaaland; Christian Focan; Bruno Coudert; Yves Humblet; Jean-Luc Canon; Antoine Adenis; Giovanni Lo Re; Carlos Carvalho; Johannes Schueller; Nicole Anciaux; Marie-Ange Lentz; Benoît Baron; Thierry Gorlia; Francis Lévi
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3562-9.
2006: Jean Bourhis; Fernando Rivera; Ricard Mesia; Ahmad Awada; Lionel Geoffrois; Christian Borel; Yves Humblet; Antonio Lopez-Pousa; Ricardo Hitt; M Eugenia Vega Villegas; Lionel DUCK; Dominique Rosine; Nadia Amellal; Armin Schueler; Andreas Harstrick
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2866-72.
2006: S Peters; Verena Voelter; Leonidas Zografos; Sandro Pampallona; R Popescu; Michel Gillet; W Bosshard; G Fiorentini; Michal Lotem; Ronny Weitzen; U Keilholz; Yves Humblet; Sophie Piperno-Neumann; Roger Stupp; Serge Leyvraz
Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):578-83.
2005: Jean-Pascal Machiels; Lionel DUCK; B Honhon; B Coster; J-C Coche; Pierre Scalliet; Yves Humblet; S Aydin; Joseph Kerger; V Remouchamps; Jean-Luc Canon; P Van Maele; L Gilbeau; S Laurent; C Kirkove; Michelle Octave-Prignot; Jean-François Baurain; Alex Kartheuser; Christine Sempoux
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(12):1898-905.
2004: David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
The New England journal of medicine 2004;351(4):337-45.
2004: Eric Van Cutsem; H van de Velde; P Karasek; Helmut Oettle; W L Vervenne; A Szawlowski; Patrick Schoffski; S Post; Chris Verslype; H Neumann; H Safran; Yves Humblet; Juan Jose Perez-Ruixo; Y Ma; Daniel Von Hoff
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1430-8.
2003: Filomena Mazzeo; Martine Berlière; Joseph Kerger; Jean Squifflet; Lionel DUCK; Véronique D'Hondt; Yves Humblet; Jacques Donnez; Jean-Pascal Machiels
Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.
Gynecologic oncology 2003;90(1):163-9.
2003: Tero Kivelä; Stefan Suciu; Johan Hansson; Wim H J Kruit; Meri-Sisko Vuoristo; O Kloke; M Gore; Marjo Hahka-Kemppinen; Leena-Maija Parvinen; Eero J Kumpulainen; Yves Humblet; Seppo Pyrhönen
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1115-20.
2003: Marc André; Etienne Baudoux; Dominique Bron; Jean-Luc Canon; Véronique D'Hondt; Marie-France Fassotte; Lionel D'Hondt; Georges Fillet; Yves Humblet; Guy Jerusalem; Philippe Vermeulen; Michel Symann; Yves Beguin
Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.
Transfusion 2003;43(1):50-7.
2003: Marie Marchand; Cornelis J A Punt; Steinar Aamdal; Bernard Escudier; Wim H J Kruit; U Keilholz; L Håkansson; Nicolas van Baren; Yves Humblet; P Mulders; M-F Avril; Alexander M M Eggermont; C Scheibenbogen; J Uiters; Jantien Wanders; M Delire; Thierry Boon; Gerrit Stoter
Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report.
European journal of cancer (Oxford, England : 1990) 2003;39(1):70-7.
2002: Vincent Grégoire; K. Kian Ang; Jean-François Rosier; Marc Beauduin; Adam S Garden; Marc Hamoir; Walter N Hittelman; Yves Humblet; Fadlo R Khuri; Luka Milas; Carine Mitine; Pierre Scalliet
A phase I study of fludarabine combined with radiotherapy in patients with intermediate to locally advanced head and neck squamous cell carcinoma.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;63(2):187-93.
2001: Johan Vansteenkiste; J E Vandebroek; Kristiaan Nackaerts; P Weynants; Y J Valcke; D A Verresen; R C Devogelaere; S A Marien; Yves Humblet; N L Dams
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(9):1221-30.
2001: Stéphane Oudard; A Caty; Yves Humblet; Marc Beauduin; E Suc; Martine Piccart; Frédéric Rolland; Pierre Fumoleau; Roland Bugat; P Houyau; Alain Monnier; X Sun; Philippe Montcuquet; J Breza; J Novak; Thierry Gil; D Chopin
Phase II study of vinorelbine in patients with androgen-independent prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(6):847-52.
2000: Bernard Vandercam; J Gérain; Yves Humblet; Augustin Ferrant; Georges Wauters; M Moreau; J Longueville; Michel Symann; Nicole Straetmans
Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
Annals of hematology 2000;79(3):152-7.
1999: Serge Leyvraz; Lucien Perey; G Rosti; A Lange; Sandro Pampallona; R Peters; Yves Humblet; Lionel Bosquée; F Pasini; M Marangolo
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3531-9.
1999: H van de Velde; Lionel Bosquée; P Weynants; Jean-Luc Canon; Jean-François Rosier; Yves Humblet
Moderate dose-escalation of combination chemotherapy with concomitant thoracic radiotherapy in limited-disease small-cell lung cancer: prolonged intrathoracic tumor control and high central nervous system relapse rate. Groupe d'Oncologie-Pneumologie Clinique de l'Université Catholique de Louvain, Brussels and Liège, Belgium.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(9):1051-7.
1999: Lionel D'Hondt; Joanne Wuu; Marc André; C Lerberghe; Thierry Guillaume; Anne-Marie Feyens; Yves Humblet; Alex Dromelet; Bernard Chatelain; J Longueville; F Stewart; Véronique D'Hondt; Michel Symann
Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation.
Bone marrow transplantation 1999;24(5):483-9.
1999: Lionel D'Hondt; Robert V B Emmons; Marc André; Thierry Guillaume; Anne-Marie Feyens; Jean-Luc Canon; Yves Humblet; J Longueville; Michel Symann
The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed.
Leukemia & lymphoma 1999;34(1-2):105-9.
1999: Thierry Guillaume; Daniel B Rubinstein; K S Zaner; Yves Humblet; Michel Symann
Autologous peripheral blood stem cell transplantation for lung cancer.
Baillière's best practice & research. Clinical haematology 1999;12(1-2):233-46.
1999: Marie Marchand; Nicolas van Baren; P Weynants; Vincent G Brichard; Brigitte Dréno; Marie-Hélène Tessier; E Rankin; G Parmiani; F Arienti; Yves Humblet; A Bourlond; R Vanwijck; D Liénard; Marc Beauduin; P Y Dietrich; V Russo; Joseph Kerger; G Masucci; E Jäger; J De Greve; J Atzpodien; Francis Brasseur; Pierre G Coulie; Pierre van der Bruggen; Thierry Boon
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.
International journal of cancer. Journal international du cancer 1999;80(2):219-30.
1998: Eric Van Cutsem; Carmelo Pozzo; H Starkhammar; L Dirix; Edmondo Terzoli; F Cognetti; Yves Humblet; Carlo Garufi; Ludo Filez; G Gruia; C Cote; Carlo Barone
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(11):1199-204.
1997: Lionel D'Hondt; Marc André; Jean-Luc Canon; Thierry Guillaume; Chantal Doyen; Anne-Marie Feyens; Bernard Chatelain; Alex Dromelet; Yves Humblet; J Longueville; Michel Symann
[Efficiency of high-dose FEC chemotherapy for the mobilization of hematopoietic stem cells into peripheral blood].
Bulletin du cancer 1997;84(7):729-33.
1997: Lionel D'Hondt; Marc André; Thierry Guillaume; Anne-Marie Feyens; Yves Humblet; Chantal Doyen; André Bosly; Alex Dromelet; Bernard Chatelain; Michel Symann
Quantification of CD34+ cells mobilized into the peripheral blood predicts the yield of the leukapheresis product and can replace progenitor assays.
Cytokines, cellular & molecular therapy 1997;3(1):21-6.
1997: Lionel D'Hondt; Thierry Guillaume; Yves Humblet; Michel Symann
Digital necrosis associated with chronic myeloid leukemia: a rare paraneoplastic phenomenon ... and not a toxicity of recombinant interferon.
Acta clinica Belgica 1997;52(1):49.
1996: Lionel D'Hondt; B Filleul; Thierry Guillaume; Yves Humblet; J Longueville; R Willocx; Michel Symann
Severe anal condylomata acuminata following high-dose chemotherapy and autologous hematopoietic stem cell transplantation: a case report.
Acta gastro-enterologica Belgica 1996;59(4):254-5.
1996: Lucien Perey; G Rosti; A Lange; Sandro Pampallona; Lionel Bosquée; Felice Pasini; Yves Humblet; O Hamdan; Gian Luigi Cetto; M Marangolo; Serge Leyvraz
Sequential high-dose ICE chemotherapy with circulating progenitor cells (CPC) in small cell lung cancer: an EBMT study.
Bone marrow transplantation 1996;18 Suppl 1():S40-3.
1996: Yves Humblet; Lionel Bosquée; P Weynants; M Symann
High-dose chemo-radiotherapy cycles for LD small cell lung cancer patients using G-CSF and blood stem cells.
Bone marrow transplantation 1996;18 Suppl 1():S36-9.
1995: M Marchand; P Weynants; E Rankin; F Arienti; F Belli; G Parmiani; N Cascinelli; A Bourlond; R Vanwijck; Yves Humblet
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3.
International journal of cancer. Journal international du cancer 1995;63(6):883-5.
1995: Francis Brasseur; Donata Rimoldi; D Liénard; Bernard Lethé; S Carrel; F Arienti; L Suter; R Vanwijck; A Bourlond; Yves Humblet
Expression of MAGE genes in primary and metastatic cutaneous melanoma.
International journal of cancer. Journal international du cancer 1995;63(3):375-80.
1995: Véronique D'Hondt; Yves Humblet; Thierry Guillaume; S Baatout; C Chatelain; M Berlière; J Longueville; Anne-Marie Feyens; J de Greve; A Van Oosterom
Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.
Blood 1995;85(9):2347-53.
1995: Lionel D'Hondt; Thierry Guillaume; Yves Humblet; M Moriau; J M Lachapelle; Michel Symann
Digital necrosis associated with chronic myeloid leukemia: a rare paraneoplastic phenomenon.
Acta clinica Belgica 1995;50(5):297-300.
1995: C Stenier; A Bourlond; Yves Humblet
Ki-1 anaplastic primary cutaneous large-cell lymphoma.
Dermatology (Basel, Switzerland) 1995;190(4):332-4.
1994: Véronique D'Hondt; Thierry Guillaume; Yves Humblet; Chantal Doyen; B Chatelain; Anne-Marie Feyens; P Staquet; J C Osselaer; B Müll; Michel Symann
Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.
Bone marrow transplantation 1994;13(3):261-4.
1993: Véronique D'Hondt; P Weynants; Yves Humblet; Thierry Guillaume; Jean-Luc Canon; Marc Beauduin; P Duprez; J Longueville; R Müll; C Chatelain
Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized phase Ib study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2063-71.
1993: Thierry Guillaume; O Hamdan; P Staquet; M Sekhavat; B Chatelain; André Bosly; D B Rubinstein; Yves Humblet; C Doyen; Bertrand Coiffier
Blunted rise in intracellular calcium in CD4+ T cells in response to mitogen following autologous bone marrow transplantation.
British journal of haematology 1993;84(1):131-6.
1992: André Bosly; Thierry Guillaume; P Brice; Yves Humblet; P Staquet; C Doyen; B Chatelain; C R Franks; C Gisselbrecht; Michel Symann
Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Experimental hematology 1992;20(8):962-8.
1991: Vincent Grégoire; Marc Beauduin; Yves Humblet; M Hamoir; J Longueville; F Majois; F M Remacle; F Rousseau; E Salamon; André Wambersie
A phase I-II trial of induction chemotherapy with carboplatin and fluorouracil in locally advanced head and neck squamous cell carcinoma: a report from the UCL-Oncology Group, Belgium.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(8):1385-92.
1990: P Weynants; Yves Humblet; Jean-Luc Canon; M Symann
Biology of small cell lung cancer: an overview.
The European respiratory journal 1990;3(6):699-714.
1990: André Bosly; P Brice; Yves Humblet; Chantal Doyen; A Faille; B Chatelain; C Franks; C Gisselbrecht; Michel Symann
Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease.
Nouvelle revue française d'hématologie 1990;32(1):13-6.
1990: P Weynants; Yves Humblet; André Bosly; D Schallier; P Duprez; F Majois; Marc Beauduin; J Prignot; Michel Symann
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).
Medical oncology and tumor pharmacotherapy 1990;7(4):219-22.
1990: Jean-Luc Canon; Yves Humblet; M Symann
Resistance to cisplatin: how to deal with the problem?
European journal of cancer (Oxford, England : 1990) 1990;26(1):1-3.
1989: Michel Symann; Yves Humblet; André Bosly; Jean-Luc Canon; Chantal Doyen; J Longueville
[Therapeutic intensification with bone marrow autografting in adults].
Pathologie-biologie 1989;37(9):969-72.
1989: Yves Humblet; Anne-Marie Feyens; M Sekhavat; D Agaliotis; Jean-Luc Canon; Michel Symann
Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts.
Cancer research 1989;49(18):5058-61.
1989: Yves Humblet; P Weynants; André Bosly; F Majois; P Duprez; C Francis; Marc Beauduin; Jean-Pascal Machiels; C Gailly; Luc Delaunois
Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group.
Medical oncology and tumor pharmacotherapy 1989;6(3):207-12.
1989: M Symann; Yves Humblet; A Bosly
[Clinical and biological aspects of intensive chemotherapy with autologous bone marrow grafts in small-cell bronchial cancer].
Bulletin et mémoires de l'Académie royale de médecine de Belgique 1989;144(3-4):213-21; discussion 222-3.
1988: Jean-Luc Canon; Yves Humblet; A M Lebacq-Verheyden; P Manouvriez; H Bazin; J Rodhain; J Prignot; Michel Symann
Immunodetection of small cell lung cancer metastases in bone marrow using three monoclonal antibodies.
European journal of cancer & clinical oncology 1988;24(2):147-50.
1988: A M Lebacq-Verheyden; A Neirynck; A M Ravoet; Yves Humblet; H Oie; I Linnoila; A F Gazdar; J D Minna; Michel Symann
Monoclonal antibodies for the in vitro detection of small cell lung cancer metastases in human bone marrow.
European journal of cancer & clinical oncology 1988;24(2):137-45.
1988: Yves Humblet; P Lefebvre; J L Jacques; André Bosly; Anne-Marie Feyens; M Sekhavat; D Agaliotis; Michel Symann
Concentration of bone marrow progenitor cells by separation on a Percoll gradient using the Haemonetics model 30.
Bone marrow transplantation 1988;3(1):63-7.
1988: Yves Humblet; Michel Symann
Detection of small cell lung cancer bone marrow metastases by tumor stem cell assay.
Pathologie-biologie 1988;36(1):83-5.
1988: Yves Humblet; Jean-Luc Canon; M Sekhavat; Anne-Marie Feyens; P Manouvriez; A M Lebacq-Verheyden; H Bazin; J Prignot; Michel Symann
Detection of small cell lung cancer bone marrow metastases by immunofluorescence.
Pathologie-biologie 1988;36(1):25-8.
1987: Yves Humblet; Michel Symann; André Bosly; Luc Delaunois; C Francis; Jean-Pascal Machiels; Marc Beauduin; Chantal Doyen; P Weynants; J Longueville
Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(12):1864-73.
1987: A E Bosly; P J Staquet; C M Doyen; B J Chatelain; Yves Humblet; M L Symann
Recombinant human interleukin-2 restores in vitro T-cell colony formation by peripheral blood mononuclear cells after autologous bone marrow transplantation.
Experimental hematology 1987;15(10):1048-54.
1986: F Ceulemans; Yves Humblet; A Bosly; M Symann; A Trouet
A phase I study of vinblastine tryptophan ester.
Cancer chemotherapy and pharmacology 1986;18(1):44-6.
1984: K E Willard-Gallo; Yves Humblet; M Symann
Leukocyte membrane proteins in chronic lymphocytic leukemia, as studied by two-dimensional gel electrophoresis.
Clinical chemistry 1984;30(12 Pt 1):2069-77.